Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclarion, Inc. (ACON)
NASDAQ:ACON
Holding ACON?
Track your performance easily
ACON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.10 - $6.75
Previous Close$0.12
Volume2.17M
Average Volume (3M)645.88K
Market Cap
$1.30M
Enterprise Value-$8.29K
Total Cash (Recent Filing)$1.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Aug 25, 2023EPS Estimate
-$1.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding10,431,159
10 Day Avg. Volume2,045,113
30 Day Avg. Volume645,879
Standard Deviation0.25
R-Squared0.00720
Alpha-0.11
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.52
Price to Sales (P/S)26.43
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.15
Enterprise Value/Gross Profit25.57
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.30Price Target Upside940.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aclarion, Inc. News
Bulls Say, Bears Say
Bulls Say
Market Coverage75% of major payers in London now cover Nociscan.
Market InterestAclarion has successfully garnered interest from Key Opinion Leaders and medical payers.
Strategic InitiativesThe strategic initiatives to expand the reach of Nociscan, including partnerships and clinical trials, represent opportunities to validate the technology and strengthen market adoption.
Bears Say
Capital RequirementsAclarion needs to raise additional capital to fund its operations, which could lead to further share dilution.
Financial PerformanceThe company reported revenue and operating expenses below expectations, with a GAAP loss per share narrower than anticipated.
Stock Listing ComplianceACON did not meet the minimum closing bid requirement for continued listing on the Nasdaq exchange and plans a reverse stock split to regain compliance.
---
Ownership Overview
9.90%
Insiders
0.40% Mutual Funds
<0.01% Other Institutional Investors
89.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ACON FAQ
What was Aclarion, Inc.’s price range in the past 12 months?
Aclarion, Inc. lowest stock price was $0.10 and its highest was $6.75 in the past 12 months.
What is Aclarion, Inc.’s market cap?
Currently, no data Available
When is Aclarion, Inc.’s upcoming earnings report date?
Aclarion, Inc.’s upcoming earnings report date is Aug 25, 2023 which is 486 days ago.
How were Aclarion, Inc.’s earnings last quarter?
Currently, no data Available
Is Aclarion, Inc. overvalued?
According to Wall Street analysts Aclarion, Inc.’s price is currently Undervalued.
Does Aclarion, Inc. pay dividends?
Aclarion, Inc. does not currently pay dividends.
What is Aclarion, Inc.’s EPS estimate?
Aclarion, Inc.’s EPS estimate is -$1.44.
How many shares outstanding does Aclarion, Inc. have?
Aclarion, Inc. has 10,438,859 shares outstanding.
What happened to Aclarion, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aclarion, Inc.?
Currently, no hedge funds are holding shares in ACON
---
Aclarion, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.30 (940.83% Upside)
$1.30 (940.83% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-97.77%
12-Months-Change
Fundamentals
Return on Equity
-745.47%
Trailing 12-Months
Asset Growth
106.58%
Trailing 12-Months
Company Description
Aclarion, Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.
---
ACON Stock 12 Month Forecast
Average Price Target
$1.30
▲(940.83% Upside)
Technical Analysis
Brainstorm Cell Therapeutics
―
Cellectar Biosciences
―
Corbus Pharmaceuticals
―
Geron
―
Best Analysts Covering ACON
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-46.97%
assigned a buy rating 27 days ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -46.97% per trade.
---